Table 1. Histology and clinical characteristics of primary ovarian tumors.

Tumor No.	Histology	Stage	PatientAge	CA125 (U/mL)	Menopausal Status	Elevated Risk
CC-T1	Clear Cell	IA	51	25	Peri	N
CC-T2	Clear Cell	IC	58	24	Post	N
CC-T3	Clear Cell	IC	45	705	Peri	N
E-T1	Endometrioid	IIIC	75	112	Post	N
E-T2	Endometrioid	IIB	43	207	Pre	N
E-T3	Endometrioid	IIIC	58	2662	Post	Y
E-T4	Endometrioid	IIA	58	75	Post	Y
E-T5	Endometrioid	IA	55	372	Post	N
E-T6	Endometrioid	IB	46	3897	Peri	N
E-T7	Endometrioid	IB	47	5201	Post	N
E-T8	Endometrioid	IC	38	1720	Post	Y
E-T9	Endometrioid	IIIB	51	2301	Post	N
S-T1	Serous	IIIC	82	134	Post	N
S-T2	Serous	IVA	58	6706	Post	N
S-T3	Serous	IIIC	77	1828	Post	N
S-T4	Serous	IIIC	74	994	Post	N
S-T5	Serous	IIIC	43	480	Pre	N
S-T6	Serous	IIIC	70	1504	Post	N
S-T7	Serous	IIIC	74	1023	Post	Y
S-T8	Serous	IIIC	56	396	Post	N
S-T9	Serous	IIIC	69	835	Post	N
S-T10	Serous	IIIC	59	4626	Post	N
S-T11	Serous	IIIC	48	12	Post	Y
S-T12	Serous	IIIC	68	49	Post	N
S-T13	Serous	IIIC	49	195	Peri	N
S-T14	Serous	IIIC	42	1075	Pre	N
S-T15	Serous	IIIC	49	8000	Post	N

Menopausal Status was recorded as follows: Post  =  age> =  55 or self-reported menopause, hormone replacement therapy, hysterectomy or oophorectomy; Peri  =  age<55 and inconsistent menstruation; Pre  =  age<55 and menstruating (See Appendix S1). Elevated Risk was recorded as follows: Y if one or more of the following conditions were met: a) family history of ovarian or breast cancer; b) Ashkenazi Jewish ethnicity and family history of breast cancer; c) BRCA1 or 2 mutation; d) mutation status unknown and family history of BRCA1 or 2 mutation [64].